汇宇制药-W
(688553)
| 流通市值：84.10亿 | | | 总市值：103.70亿 |
| 流通股本：3.44亿 | | | 总股本：4.24亿 |
| 报告期 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 453,118,838.7 | 239,052,524.64 | 1,094,382,336.85 | 851,844,303.21 |
| 营业收入 | 453,118,838.7 | 239,052,524.64 | 1,094,382,336.85 | 851,844,303.21 |
| 二、营业总成本 | 429,857,375.39 | 209,039,659.41 | 1,006,585,170.23 | 741,467,771.85 |
| 营业成本 | 93,324,746.27 | 39,158,727.24 | 181,511,412.22 | 143,515,070.74 |
| 税金及附加 | 4,173,827.78 | 1,225,270.8 | 7,910,228.78 | 4,728,199.32 |
| 销售费用 | 173,514,766.45 | 93,561,450.97 | 431,089,814.91 | 326,663,876.33 |
| 管理费用 | 41,580,805.16 | 22,137,967.87 | 80,468,747.88 | 55,233,228.17 |
| 研发费用 | 149,419,089.98 | 61,856,632.31 | 327,724,906.96 | 225,022,804.88 |
| 财务费用 | -32,155,860.25 | -8,900,389.78 | -22,119,940.52 | -13,695,407.59 |
| 其中:利息费用 | 5,269,676.79 | 1,797,026.94 | 12,403,269.02 | 9,988,609.6 |
| 其中:利息收入 | 22,672,078.36 | 8,480,289.7 | 36,416,228.9 | -23,234,579.08 |
| 三、其他经营收益 | | | | |
| 加:公允价值变动收益 | -146,324,714.95 | -81,849,444.82 | 239,856,212.2 | 115,503,121.76 |
| 加:投资收益 | 3,029,759.73 | 703,249.21 | 13,815,175.53 | 15,370,176.68 |
| 资产处置收益 | 1,887.15 | - | -301,236.61 | - |
| 资产减值损失(新) | 102,518.99 | -1,685,087.14 | -14,813,594.43 | -9,604,942.95 |
| 信用减值损失(新) | -300,923.45 | -217,008.62 | 1,810,843.07 | -1,595,659.56 |
| 其他收益 | 13,881,937.44 | 9,215,405.84 | 20,267,889.31 | 14,368,447.3 |
| 四、营业利润 | -106,348,071.78 | -43,820,020.3 | 348,432,455.69 | 244,417,674.59 |
| 加:营业外收入 | 1,388,146.7 | 716,722 | 7,588,498.18 | 7,232,262.6 |
| 减:营业外支出 | 44,972.19 | 30,886.72 | 6,322,077.17 | 1,597,389.62 |
| 五、利润总额 | -105,004,897.27 | -43,134,185.02 | 349,698,876.7 | 250,052,547.57 |
| 减:所得税费用 | -21,409,443.12 | -16,448,635.67 | 33,801,654.4 | 29,287,036.19 |
| 六、净利润 | -83,595,454.15 | -26,685,549.35 | 315,897,222.3 | 220,765,511.38 |
| (一)按经营持续性分类 | | | | |
| 持续经营净利润 | -83,595,454.15 | -24,119,744.57 | 315,897,222.3 | 220,765,511.38 |
| (二)按所有权归属分类 | | | | |
| 归属于母公司股东的净利润 | -80,720,507.81 | -25,626,485.3 | 325,390,295.3 | 227,352,384.74 |
| 少数股东损益 | -2,874,946.34 | -1,059,064.05 | -9,493,073 | -6,586,873.36 |
| 扣除非经常损益后的净利润 | 48,073,129.6 | 34,410,939.35 | 92,117,061.3 | 100,232,159.57 |
| 七、每股收益 | | | | |
| (一)基本每股收益 | -0.19 | -0.06 | 0.77 | 0.54 |
| (二)稀释每股收益 | -0.19 | -0.06 | 0.77 | 0.54 |
| 八、其他综合收益 | -2,483,729.31 | -602,978.36 | 910,833.69 | 1,952,448.71 |
| 归属于母公司股东的其他综合收益 | -2,483,729.31 | -602,978.36 | 910,833.69 | 1,952,448.71 |
| 九、综合收益总额 | -86,079,183.46 | -27,288,527.71 | 316,808,055.99 | 222,717,960.09 |
| 归属于母公司股东的综合收益总额 | -83,204,237.12 | -26,229,463.66 | 326,301,128.99 | 229,304,833.45 |
| 归属于少数股东的综合收益总额 | -2,874,946.34 | -1,059,064.05 | -9,493,073 | -6,586,873.36 |
| 公告日期 | 2025-08-30 | 2025-04-26 | 2025-04-26 | 2024-10-26 |
| 审计意见(境内) | | | 标准无保留意见 | |